OPB 9195

Drug Profile

OPB 9195

Latest Information Update: 14 May 2003

Price : $50

At a glance

  • Originator Otsuka Pharmaceutical
  • Class Antihyperglycaemics; Small molecules; Thiadiazoles; Thiazolidines
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Diabetic complications

Most Recent Events

  • 14 May 2003 No development reported - Preclinical for Diabetic complications in Japan (unspecified route)
  • 28 Mar 2003 A preclinical study has been added to the Diabetes pharmacodynamics section
  • 19 Oct 2000 A study has been added to the Diabetes pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top